Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.
about
A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.Risk factors for relapse after allogeneic transplantation in acute myeloid leukemiaTreatment of Acute Myeloid Leukemia in Adolescent and Young Adult PatientsAllogeneic stem cell transplantation in first complete remissionA novel acquired inv(2)(p23.3q24.3) with concurrent submicroscopic deletions at 2p23.3, 2p22.1, 2q24.3 and 1p13.2 in a patient with chronic thrombocytopenia and anemiaEx vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR.Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemiaHLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia.Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials networClassifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research studyEfficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective StudiesThe role of allogeneic transplantation in high-risk acute myelogenous leukemia.Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMTMatched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMTBusulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission.Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia.Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patientsAn approach to the management of leukemia in the developing world.Current therapeutic strategies for acute myeloid leukaemia.Allogeneic stem cell transplantation in acute myeloid leukemiaAutologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation ResearchGuidelines on the management of acute myeloid leukaemia in adults.Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia.Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.Interactive diagnostics in the indication to allogeneic SCT in AML.Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation.Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification.
P2860
Q24536117-8BB778F1-376D-427B-BD7B-637B6EB2F54BQ26771438-0179918F-4DBA-49DF-8294-3E8F223F583BQ26799609-FD7E6F92-A5DE-42E5-B97D-B563CDFBDF4EQ26996818-610CD413-AE0D-4F36-AAEF-3CC68754EE06Q33420184-E3A40006-10B3-46CF-9801-3191B7165190Q33760933-2A99AE4F-986E-44AF-A8B4-1C0421AA1F47Q33881750-EF19B89F-1BF9-43EE-BBEE-D7470AE91CFCQ34166581-AD38DAD0-8CDA-433E-9A5C-423C8E45856BQ34167404-73DD4B03-E79C-4CF4-844D-BA0937B30724Q34297698-1527D16A-DDE9-4DD6-9438-055DB432609FQ34316768-F4BE5E3D-F065-4A60-80CE-8E1757D3B6FCQ34572795-15C46744-D013-4126-8CD2-540E465A0D82Q34583041-2ED8352D-D6C6-4C64-A5FE-86AFB536128FQ34608688-52EE2C29-91F2-43A0-BB56-6F7EBA05C301Q34620456-F855894F-2A37-4F01-93CA-FF659782A0D6Q35148420-A41A8F2C-CB6B-4262-B437-D72BAC656B60Q35574597-C2BA0F9A-66DA-463C-96DB-06DEC53BD1E1Q35703480-3F409A15-3963-4307-AA27-42501D6B03E1Q35903540-423CF2B6-3477-491E-886F-549181E06015Q35953348-D115DA6C-5772-4F3B-AAFE-4719F187AA92Q36036605-4B7B4531-38B9-4C48-9822-53FE09866D44Q36121885-3FEC31BE-C7A6-4E4B-87AC-087CE1A10DADQ36153495-BC7B8B68-FF64-4575-BB49-66012637FD72Q36255287-EB98B701-8C9C-4C67-BCEB-DC0C4B9987E7Q36337955-8A8B9333-D77D-4225-8084-61D12C83D755Q36481195-49337EE3-3564-4D80-9CB3-1ECDC7A1E3BBQ36539598-4A527FBF-DBB7-4626-82ED-7CF7110C3887Q36562937-4D555051-9D39-4B93-B19E-E427B6C6CE32Q36579065-536617F7-D763-41AE-8DA9-0D5D9E45A9E6Q36630107-C089DD86-42B6-40E7-9FFD-BFE8229C414BQ37061964-A42BE713-69D4-4420-A24A-05CEEB5BA976Q37061969-E5FA450E-1C78-4B9C-B6CD-1F11BA9BD18AQ37159533-816C8706-940B-48F4-B568-766F66454DBAQ37323006-78B5E7AE-D377-4405-81F6-1B91D1D2D084Q37334588-475FD43D-5941-4E19-9400-43D7E5A86952Q37345807-30E9DB32-150D-4D5B-AC13-C131752ECA93Q37419348-ECAC55AC-DBD8-4747-B36D-C41B84580D61Q37442649-DF5DAF9F-C834-454A-988A-29DF38A9FD14Q37486793-290F9E22-5D3E-45EA-819D-D834E21C6057Q37559330-B7ACA9A7-65C8-4D51-820C-977866779564
P2860
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Allogeneic compared with autol ...... the EORTC/GIMEMAAML-10 trial.
@ast
Allogeneic compared with autol ...... the EORTC/GIMEMAAML-10 trial.
@en
Allogeneic compared with autol ...... rs with acute myeloid leukemia
@nl
type
label
Allogeneic compared with autol ...... the EORTC/GIMEMAAML-10 trial.
@ast
Allogeneic compared with autol ...... the EORTC/GIMEMAAML-10 trial.
@en
Allogeneic compared with autol ...... rs with acute myeloid leukemia
@nl
prefLabel
Allogeneic compared with autol ...... the EORTC/GIMEMAAML-10 trial.
@ast
Allogeneic compared with autol ...... the EORTC/GIMEMAAML-10 trial.
@en
Allogeneic compared with autol ...... rs with acute myeloid leukemia
@nl
P2093
P1433
P1476
Allogeneic compared with autol ...... the EORTC/GIMEMAAML-10 trial.
@en
P2093
Amine Belhabri
Anne Hagemeijer
Boris Labar
EORTC and GIMEMA Leukemia Groups
Eugenio Gallo
Franco Mandelli
Gennaro De Rosa
Giuseppe Fioritoni
Giuseppe Leone
Jean-Henri Bourhis
P304
P356
10.1182/BLOOD-2002-12-3714
P407
P577
2003-04-24T00:00:00Z